Diabetes and the role of isoprenoid biosynthesis.
Bliznakov
Emile G
EG
D000255:Adenosine Triphosphate / Q000378:metabolism; D000924:Anticholesteremic Agents / Q000494:pharmacology; D001692:Biological Transport / Q000187:drug effects; D002784:Cholesterol / Q000096:biosynthesis; D002986:Clinical Trials as Topic; D003067:Coenzymes; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000378:metabolism*; D005947:Glucose / Q000378:metabolism; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D008148:Lovastatin / Q000494:pharmacology; D017368:Protein Prenylation; D013729:Terpenes / Q000378:metabolism*; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D003067:Coenzymes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D013729:Terpenes; D014451:Ubiquinone; D000255:Adenosine Triphosphate; D002784:Cholesterol; D008148:Lovastatin; C024989:coenzyme Q10; D005947:Glucose